TMDX Company Profile and Key Details

TMDX has shown sold momentum, gaining 5.4% over the past week and 20.66% over the past quarter, though year-to-date performance is up 16.67%. Short-term trend indicators are bearishly aligned (SMA20 -5.8%, SMA50 -3.39%, SMA200 5.73%). The stock’s 14-day RSI is 42.88 (neutral), while the ATR of 7.03 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -16.92% below its high and over 108.79% above its low. Average 10-day trading volume of 783.43 thousand shares is in line with the 3-month average of 763.04 thousand, indicating normal recent market interest.

TransMedics Group, Inc. (NASDAQ:TMDX) closed at $129.60 USD, losing -$0.77 (-0.59%) from the previous close of $130.37. The stock is currently mid-range between its 52-week high and low $62.07 and $156.00. With a market capitalization of about $4.43 billion, TransMedics Group, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.98). Key stats such as the average daily volume over the past year has been around 766.55 thousand shares, in line with its 52-week average. Headquartered in Andover, MA, TransMedics Group, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Waleed H. Hassanein, the company employs approximately 728 people and listed since May 02, 2019. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

TransMedics Group, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.09. This means the shares are trading below this model’s fair value.

Wall Street analysts project EPS growth of 52.57% annually over the next five years. The latest quarter delivered EPS of $0.66. The next quarter is forecast at $0.39. Next year's EPS is expected at $44.85. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 8 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $166.00 to $104.00. The high target offers 28.09% upside. The low target suggests -19.75% downside. The mean target is $140.00. This offers 8.02% upside. TransMedics Group, Inc. earnings surprise history is a mixed track record. The quarter that ended October 29, 2025, missed forecasts by 78.38%. The prior quarter beat by 91.67%. Over the last six quarters, Apple has recorded several small beats. These include 66.67% in July 31, 2024.

TransMedics Group, Inc. has 34.09 million shares outstanding. The public float is 32.96 million shares, elevated short interest at 41.68% of float. This equals 8.27 million shares. The short ratio is 7.15 days. Institutional investors hold 114.66% of the float. Insiders own 2.95%. Hassanein Waleed H holds 495.01 thousand shares, TOBIN JAMES R has 173.15 thousand shares and Khayal Tamer I has 36.04 thousand shares. Over the past six months, insider transactions show net selling. They sold 13.06 thousand shares across 4 transactions.

TransMedics Group, Inc. trades at a P/E ratio of 48.22, slightly above the S&P 500 average, with a price-to-sales ratio of 7.83 and a price-to-book ratio of 12.46 reflecting a rich premium to book value. The P/FCF stands at 36.74, also above market averages. Compared to sector medians, TransMedics Group, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

TransMedics Group, Inc. (NASDAQ:TMDX) shares are up 16.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows TransMedics Group, Inc. trading at a premium to the broader market with a P/E of 48.22. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $120.74, suggesting -6.84% downside. Our AI forecast model points to short-term weakness (-0.2% over two weeks), a medium-term rise (61.47% over three months), and a longer-term gain (16.77% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that TransMedics Group, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.2%, with price expected at $129.34 by February 19, 2026, within a range of $124.66 to $134.31 3-Month Outlook: Projected rise of 61.47%, reaching $209.26 by May 05, 2026, with a range of $201.32 to $219.97. 1-Year Outlook: Projected gain of 16.77%, with price at $151.33 by February 05, 2027, within a range of $140.54 to $160.75.